NOVO INTEGRATED SCIENCES (NVOS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2024, filed Dec 18, 2024. Each column of the statement tables below links to the filing it was taken from.
NOVO INTEGRATED SCIENCES (NVOS) reported $13.3M in revenue for fiscal year 2024, up 5.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth is modest, but rising overhead and weak liquidity leave the business dependent on financing to fund operations.
Gross profit rose from$5.0M in FY2023 to$5.7M in FY2024, indicating the revenue engine produced more gross profit before overhead. Yet operating cash flow shifted from-$2.2M to-$5.1M , so improved gross economics did not become cash and the business became more reliant on non-operating funding.
Overhead absorbs the gross profit: FY2024 selling, general and administrative expense was
The balance sheet is increasingly pressured short term: liabilities represented
Financial Health Signals
NOVO INTEGRATED SCIENCES does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
NOVO INTEGRATED SCIENCES scores -4.59, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $83.2M against total assets of $32.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
NOVO INTEGRATED SCIENCES passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
NOVO INTEGRATED SCIENCES reported a net loss of $16.2M while operations used $5.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
NOVO INTEGRATED SCIENCES reported an operating loss of $10.1M against $652K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
NOVO INTEGRATED SCIENCES generated $3.1M in revenue in Q4 2024. This represents a decrease of 6.7% from the same quarter a year earlier. Against the prior quarter it is down 2.3%.
NOVO INTEGRATED SCIENCES's EBITDA was -$2.1M in Q4 2024, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
NOVO INTEGRATED SCIENCES reported $5.0M in net income in Q4 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
NOVO INTEGRATED SCIENCES earned $0.31 per diluted share (EPS) in Q4 2024. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
NOVO INTEGRATED SCIENCES recorded an outflow of $549K in free cash flow in Q4 2024, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
NOVO INTEGRATED SCIENCES held $845K in cash against $158K in long-term debt as of Q4 2024, with $14.6M of liabilities due within a year.
Not reported for Q4 2024.
Margins & Returns
NOVO INTEGRATED SCIENCES's gross margin was 51.2% in Q4 2024, indicating the percentage of revenue retained after direct costs. This is up 23.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 22.7 percentage points.
NOVO INTEGRATED SCIENCES's operating margin was -87.6% in Q4 2024, reflecting core business profitability. This is up 6.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.6 percentage points.
NOVO INTEGRATED SCIENCES's quarterly ROE was 33.6% in Q4 2024: one quarter's net income over shareholder equity, not annualized. This is up 46.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 171.6 percentage points.
Not shown for Q4 2024: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
NOVO INTEGRATED SCIENCES invested $3K in capex in Q4 2024, funding long-term assets and infrastructure. This represents a decrease of 90.0% from the same quarter a year earlier.
Not reported for Q4 2024.
Not reported for Q4 2024.
NVOS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M-6.7% | $3.2M-4.3% | $3.2M+24.0% | $3.9M+13.8% | $3.3M | $3.3M-76.2% | $2.6M-10.9% | $3.4M+8.1% |
| Cost of Revenue | $1.5M-36.7% | $2.3M+14.0% | $1.8M+16.5% | $1.9M+15.9% | $2.4M | $2.0M-82.7% | $1.6M-4.1% | $1.7M-11.4% |
| Gross Profit | $1.6M+70.0% | $897K-31.7% | $1.3M+36.4% | $1.9M+11.8% | $928K | $1.3M-45.4% | $971K-20.2% | $1.7M+37.4% |
| SG&A Expenses | $2.5M-37.5% | $3.4M+24.5% | $2.9M+3.8% | $5.3M+32.2% | $4.0M | $2.7M-24.0% | $2.8M-17.4% | $4.0M+51.4% |
| Operating Income | -$2.7Mn/m | -$2.5Mn/m | -$1.5Mn/m | -$3.3Mn/m | -$3.1M | -$1.4Mn/m | -$1.8Mn/m | -$2.2Mn/m |
| EBITDA | -$2.1Mn/m | -$2.0Mn/m | -$972Kn/m | -$2.7Mn/m | -$2.5M | -$851Kn/m | -$1.2Mn/m | -$1.7Mn/m |
| Interest Expense | $192K+220.4% | $178K+1764.6% | $139K+12.0% | $143K-14.3% | $60K | $10K-98.1% | $124K-89.9% | $167K+143.3% |
| Net Income | $5.0Mn/m | -$13.7Mn/m | -$2.7Mn/m | -$4.7Mn/m | -$3.2M | -$1.5Mn/m | -$4.6Mn/m | -$3.9Mn/m |
| EPS (Basic) | $0.31 | -$0.74 | -$0.16 | -$0.28 | -$0.13 | -$0.10n/m | -$0.59 | -$1.16 |
| EPS (Diluted) | $0.31 | -$0.74 | -$0.16 | -$0.28 | -$0.13 | -$0.10 | -$0.59 | -$1.16 |
| Diluted Shares (Avg) | N/A | 19M | 18M | 17M | N/A | 14M | 8M | 3M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
NVOS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $32.1M-9.6% | $35.3M-1.2% | $34.9M-4.2% | $37.2M-1.3% | $35.6M-13.0% | $35.7M-50.2% | $36.5M-48.1% | $37.7M-41.0% |
| Current Assets | $5.4M+23.4% | $6.2M+54.1% | $5.0M+23.9% | $6.8M+52.8% | $4.4M-23.4% | $4.0M-80.1% | $4.1M-78.7% | $4.5M-63.6% |
| Cash & Equivalents | $845K+102.9% | $1.5M+231.8% | $652K+6.9% | $1.6M+86.6% | $416K-80.9% | $464K-96.3% | $610K-96.2% | $879K-90.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $1.0M-9.6% | $1.1M+18.4% | $947K+2.4% | $1.3M+25.8% | $1.1M+25.9% | $939K+45.6% | $925K+176.6% | $1.0M+177.4% |
| Accounts Receivable | $1.9M+30.7% | $2.3M+69.6% | $2.2M+133.2% | $2.6M+174.6% | $1.5M+44.2% | $1.3M-74.3% | $924K-26.2% | $960K-43.4% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $6.6M-13.6% | $7.5M-0.2% | $7.6M+0.3% | $7.6M-0.5% | $7.6M-3.1% | $7.5M-33.6% | $7.5M-16.8% | $7.6M-15.2% |
| Total Liabilities | $17.5M+58.4% | $25.7M+171.5% | $13.1M+37.1% | $14.0M-18.2% | $11.1M-41.2% | $9.5M-65.5% | $9.5M-63.1% | $17.1M-15.8% |
| Current Liabilities | $14.6M+84.4% | $22.7M+265.2% | $10.0M+61.2% | $10.9M-13.1% | $7.9M-43.8% | $6.2M-51.2% | $6.2M-46.5% | $12.6M-19.7% |
| Non-Current Liabilities | $2.9M-6.7% | $3.0M-7.9% | $3.1M-7.4% | $3.0M-32.3% | $3.2M-33.5% | $3.2M-77.8% | $3.3M-76.5% | $4.5M-2.5% |
| Long-Term Debt | $158K-54.0% | $157K-58.4% | $158K+0.3% | $157K-0.4% | $342K+112.1% | $378K-93.0% | $157K-97.1% | $158K-98.4% |
| Total Equity | $14.9M-40.0% | $10.0M-62.5% | $22.2M-18.6% | $23.6M+12.6% | $24.8M+11.3% | $26.6M-40.1% | $27.3M-38.8% | $20.9M-52.0% |
| Retained Earnings | -$83.2Mn/m | -$88.2Mn/m | -$74.5Mn/m | -$71.7Mn/m | -$67.0Mn/m | -$63.9Mn/m | -$62.4Mn/m | -$57.8Mn/m |
NVOS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$546Kn/m | -$658Kn/m | -$1.7Mn/m | -$2.2Mn/m | -$229K-133.9% | -$858Kn/m | -$879Kn/m | -$278Kn/m |
| Depreciation & Amortization | $564K-3.5% | $557K-3.9% | $568K+2.8% | $572K-2.3% | $584K-12.8% | $580K-34.3% | $553K-28.6% | $586K-15.6% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $61K-60.5% |
| Capital Expenditures | $3K-90.0% | N/A | N/A | N/A | $30K | N/A | N/A | N/A |
| Free Cash Flow | -$549Kn/m | N/A | N/A | N/A | -$259K | N/A | N/A | N/A |
| Investing Cash Flow | -$3Kn/m | N/A | N/A | N/A | -$30K-3870.7% | N/A | N/A | N/A |
| Financing Cash Flow | -$128K-127.4% | $1.8M+101.9% | $3K-99.3% | $3.3Mn/m | $468Kn/m | $901Kn/m | $429K-95.5% | -$1.0M-173.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NVOS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.2%+23.1pp | 28.5%-11.4pp | 41.8%+3.8pp | 50.0%-0.9pp | 28.1% | 39.9%+22.5pp | 38.0%-4.4pp | 50.9%+10.8pp |
| Operating Margin | -87.6%+6.1pp | -80.0%-36.5pp | -48.6%+21.3pp | -85.3%-19.7pp | -93.7% | -43.4%-34.8pp | -69.9%+4.0pp | -65.6%-22.4pp |
| Net Margin | 162.3% | -436.0% | -86.6% | -120.3% | -95.7% | -45.5%-18.0pp | -180.8% | -115.1% |
| Return on Equity | 33.6%+46.3pp | -138.0%-132.4pp | -12.4%+4.6pp | -19.9%-1.1pp | -12.7% | -5.6%+3.0pp | -17.0%-6.2pp | -18.8%-14.7pp |
| Return on Assets | 15.6%+24.4pp | -38.9%-34.7pp | -7.9%+4.8pp | -12.6%-2.1pp | -8.9% | -4.2%+1.1pp | -12.7%-5.8pp | -10.4%-7.6pp |
| Current Ratio | 0.37-0.2x | 0.27-0.4x | 0.50-0.2x | 0.62+0.3x | 0.56+0.1x | 0.64-0.9x | 0.66-1.0x | 0.35-0.4x |
| Debt-to-Equity | 0.010.0x | 0.020.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.01-0.1x | 0.01-0.1x | 0.01-0.2x |
| Liabilities-to-Equity | 1.18+0.7x | 2.58+2.2x | 0.59+0.2x | 0.59-0.2x | 0.45-0.4x | 0.36-0.3x | 0.35-0.2x | 0.81+0.4x |
| Asset Turnover | 0.100.0x | 0.090.0x | 0.090.0x | 0.100.0x | 0.09 | 0.09-0.1x | 0.070.0x | 0.090.0x |
| FCF Margin | -17.8%-10.0pp | N/A | N/A | N/A | -7.8% | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Note: The current ratio is below 1.0 (0.37), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NOVO INTEGRATED SCIENCES NVOS | FY2024 | $13.3M | -$16.2M | N/A | $12K | — |
| IMAC HOLDINGS INC BACK | FY2024 | $72K | N/A | N/A | N/A | — |
Where NOVO INTEGRATED SCIENCES Ranks
Frequently Asked Questions
What is NOVO INTEGRATED SCIENCES's annual revenue?
NOVO INTEGRATED SCIENCES (NVOS) reported $13.3M in total revenue for fiscal year 2024. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NOVO INTEGRATED SCIENCES's revenue growing?
NOVO INTEGRATED SCIENCES (NVOS) revenue grew by 5.7% year-over-year, from $12.6M to $13.3M in fiscal year 2024.
Is NOVO INTEGRATED SCIENCES profitable?
No, NOVO INTEGRATED SCIENCES (NVOS) reported a net loss of $16.2M in fiscal year 2024.
What is NOVO INTEGRATED SCIENCES's EBITDA?
NOVO INTEGRATED SCIENCES (NVOS) had EBITDA of -$7.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does NOVO INTEGRATED SCIENCES have?
As of fiscal year 2024, NOVO INTEGRATED SCIENCES (NVOS) had $845K in cash and equivalents against $158K in long-term debt.
What is NOVO INTEGRATED SCIENCES's gross margin?
NOVO INTEGRATED SCIENCES (NVOS) had a gross margin of 43.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is NOVO INTEGRATED SCIENCES's operating margin?
NOVO INTEGRATED SCIENCES (NVOS) had an operating margin of -75.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is NOVO INTEGRATED SCIENCES's return on equity (ROE)?
NOVO INTEGRATED SCIENCES (NVOS) has a return on equity of -108.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is NOVO INTEGRATED SCIENCES's free cash flow?
NOVO INTEGRATED SCIENCES (NVOS) recorded an outflow of $5.1M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NOVO INTEGRATED SCIENCES's operating cash flow?
NOVO INTEGRATED SCIENCES (NVOS) recorded an outflow of $5.1M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are NOVO INTEGRATED SCIENCES's total assets?
NOVO INTEGRATED SCIENCES (NVOS) had $32.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are NOVO INTEGRATED SCIENCES's capital expenditures?
NOVO INTEGRATED SCIENCES (NVOS) invested $5K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is NOVO INTEGRATED SCIENCES's current ratio?
NOVO INTEGRATED SCIENCES (NVOS) had a current ratio of 0.37 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is NOVO INTEGRATED SCIENCES's debt-to-equity ratio?
NOVO INTEGRATED SCIENCES (NVOS) had a debt-to-equity ratio of 0.01 as of fiscal year 2024. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is NOVO INTEGRATED SCIENCES's liabilities-to-equity ratio?
NOVO INTEGRATED SCIENCES (NVOS) had a liabilities-to-equity ratio of 1.18 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is NOVO INTEGRATED SCIENCES's return on assets (ROA)?
NOVO INTEGRATED SCIENCES (NVOS) had a return on assets of -50.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is NOVO INTEGRATED SCIENCES's P/E ratio?
NOVO INTEGRATED SCIENCES (NVOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $12K as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NOVO INTEGRATED SCIENCES's price-to-sales ratio?
NOVO INTEGRATED SCIENCES (NVOS) trades at 0.0x sales, its market capitalization divided by $13.3M revenue, FY2024. The market capitalization is $12K as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does NOVO INTEGRATED SCIENCES's liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, NOVO INTEGRATED SCIENCES (NVOS) held $845K in cash, cash equivalents and investments, and reported an operating cash outflow of $5.1M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is NOVO INTEGRATED SCIENCES's Altman Z-Score?
NOVO INTEGRATED SCIENCES (NVOS) has an Altman Z-Score of -4.59, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is NOVO INTEGRATED SCIENCES's Piotroski F-Score?
NOVO INTEGRATED SCIENCES (NVOS) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NOVO INTEGRATED SCIENCES's earnings high quality?
NOVO INTEGRATED SCIENCES (NVOS) reported a net loss of $16.2M while operations used $5.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can NOVO INTEGRATED SCIENCES cover its interest payments?
NOVO INTEGRATED SCIENCES (NVOS) reported an operating loss of $10.1M against $652K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.